Adiguzel, Ahmet2024-08-042024-08-0420222667-663Xhttps://doi.org/10.4328/ACAM.21059https://hdl.handle.net/11616/103482Aim: Lacosamide, a third-generation antiepileptic drug, is used as adjunctive treatment of partial-onset seizures. It is mainly eliminated through the kidneys. The drug acts by enhancing the slow inactivation of voltage-gated sodium channels. The aim of this study was to investigate the long-term effects of lacosamide on renal function. Material and Methods: The study included two groups of patients with epilepsy (those treated and those not treated with lacosamide) and a healthy control group. Plasma creatinine, blood urea nitrogen, glomerular filtration rate (GFR; by the Modification of Diet in Renal Disease formula), and sodium levels were calculated for the participants at four retrospective time points over 6 years (t0-t1-t2-t3). Results: A total of 123 (female/male=58/65) participants, with a mean age of 33.9 +/- 9.5 years, were included in the study. The study covered a total period of 57.7 +/- 5.5 months. GFRs calculated at all time points for the group receiving lacosamide (GFR0:123.1 mL/min/1.73m2, GFR1:115.1 mL/min/1.73m2, GFR2:112.9 mL/min/1.73m2, and GFR3:102.3 mL/min/1.73m2) were lower than those of the healthy control group (p<0.05). GFR 3 levels was calculated to be lower in patients treated with lacosamide than in patients not treated with lacosamide (p < 0.05).On performing statistical analysis, higher plasma Cr0.2.3 levels were found for the group using lacosamide compared to the healthy control group (p<0.05). Discussion: In this study, all parameters evaluated to investigate the effect of lacosamide on renal functions were found to be within normal ranges in each group. However, plasma GFR levels were found to be lower in the group using lacosamide compared to the control group.eninfo:eu-repo/semantics/openAccessLacosamideAntiepileptic DrugsGFRSodium Channel BlockerSeizureArticle13111510.4328/ACAM.21059WOS:000769939400003N/A